Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

Scott M. Hammer, Magdalena E. Sobieszczyk, Holly Janes, Shelly T. Karuna, Mark J. Mulligan, Doug Grove, Beryl A. Koblin, Susan P. Buchbinder, Michael C. Keefer, Georgia D. Tomaras, Nicole Frahm, John Hural, Chuka Anude, Barney S. Graham, Mary E. Enama, Elizabeth Adams, Edwin DeJesus, Richard M. Novak, Ian Frank, Carter BentleyShelly Ramirez, Rong Fu, Richard A. Koup, John R. Mascola, Gary J. Nabel, David C. Montefiori, James Kublin, M. Juliana McElrath, Lawrence Corey, Peter B. Gilbert

Research output: Contribution to journalArticlepeer-review

388 Scopus citations


BACKGROUND: A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime-recombinant adenovirus type 5 boost (DNA/rAd5) vaccine regimen in persons at increased risk for HIV-1 infection in the United States. METHODS: At 21 sites, we randomly assigned 2504 men or transgender women who have sex with men to receive the DNA/rAd5 vaccine (1253 participants) or placebo (1251 participants). We assessed HIV-1 acquisition from week 28 through month 24 (termed week 28+ infection), viral-load set point (mean plasma HIV-1 RNA level 10 to 20 weeks after diagnosis), and safety. The 6-plasmid DNA vaccine (expressing clade B Gag, Pol, and Nef and Env proteins from clades A, B, and C) was administered at weeks 0, 4, and 8. The rAd5 vector boost (expressing clade B Gag-Pol fusion protein and Env glycoproteins from clades A, B, and C) was administered at week 24. RESULTS: In April 2013, the data and safety monitoring board recommended halting vaccinations for lack of efficacy. The primary analysis showed that week 28+ infection had been diagnosed in 27 participants in the vaccine group and 21 in the placebo group (vaccine efficacy, -25.0%; 95% confidence interval, -121.2 to 29.3; P=0.44), with mean viral-load set points of 4.46 and 4.47 HIV-1 RNA log10 copies per milliliter, respectively. Analysis of all infections during the study period (41 in the vaccine group and 31 in the placebo group) also showed lack of vaccine efficacy (P=0.28). The vaccine regimen had an acceptable side-effect profile. CONCLUSIONS: The DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00865566.)

Original languageEnglish (US)
Pages (from-to)2083-2092
Number of pages10
JournalNew England Journal of Medicine
Issue number22
StatePublished - 2013
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine'. Together they form a unique fingerprint.

Cite this